Botulinum toxin-A treatment reduces human mechanical pain sensitivity and mechanotransduction.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 24550077.
- Also identified by DOI 10.1002/ana.24122 and PMC identifier 4112716.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The mechanisms underlying the analgesic effects of botulinum toxin serotype A (BoNT-A) are not well understood. We have tested the hypothesis that BoNT-A can block nociceptor transduction. Intradermal administration of BoNT-A to healthy volunteers produced a marked and specific decrease in noxious mechanical pain sensitivity, whereas sensitivity to low-threshold mechanical and thermal stimuli was unchanged. BoNT-A did not affect cutaneous innervation. In cultured rodent primary sensory neurons, BoNT-A decreased the proportion of neurons expressing slowly adapting mechanically gated currents linked to mechanical pain transduction. Inhibition of mechanotransduction provides a novel locus of action of BoNT-A, further understanding of which may extend its use as an analgesic agent.
Medical subject headings
- Botulinum Toxins, Type A
- Hyperalgesia
- Mechanotransduction, Cellular
- Pain Threshold